Intellia slumps after co pauses late-stage trials of gene-editing treatment

Shares of gene-editing firm Intellia Therapeutics NTLA.O down 60% to $61.02 premarket

Co pauses patient dosing in late-stage trials of its experimental gene-editing treatment called nex-z in a type of protein buildup disease

NTLA says pause follows severe liver side effects in one patient dosed in late-stage trial

Co consulting experts and regulators on next steps - NTLA

Over 450 patients estimated to have received nex-z so far, Co said

Up to last close, stock down 120% YTD